Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 9, 2004
Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosisR Ehling, A Lutterotti, J Wanschitz, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|October 9, 2004
Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativityC Gneiss, M Reindl, A Lutterotti, et al.Tissue Antigens|December 4, 2003
Genetic variants in the tumor necrosis factor receptor II gene in patients with multiple sclerosisR Ehling, Ch Gassner, A Lutterotti, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|May 26, 2009
High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot studyA Millonig, D Rudzki, M Hölzl, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|March 5, 2011
Olfactory threshold is impaired in early, active multiple sclerosisA Lutterotti, M Vedovello, M Reindl, et al.European Journal of Neurology|August 18, 2018
Improvement of medical judgments by numerical training in patients with multiple sclerosisL Zamarian, M Delazer, R Ehling, et al.Journal of Neuroimmunology|March 25, 2006
Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodiesC Gneiss, P Tripp, R Ehling, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|July 18, 2008
Smoking is a risk factor for early conversion to clinically definite multiple sclerosisF Di Pauli, M Reindl, R Ehling, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|February 1, 2007
Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patientsC Gneiss, P Tripp, F Reichartseder, et al.Pageof 2